Gilead Sciences narrowly beat sales expectations for its HIV PrEP drug, Yeztugo. Gilead stock slipped, still in a downtrend.

CRISPR therapy EBT-101 targeted HIV DNA inside living humans for the first time, showing strong safety results but failing to prevent viral rebound after ART stopped.

Sorry, but your browser does not support the video tag. (BPT) - HIV was once considered a terminal diagnosis. However, this once life-threatening disease is now a ...

It is an incurable sexually transmitted infection that weakens your immune system and could cause AIDS if left untreated. Having untreated HIV can also increase your risk for other health problems as ...

May 11 (Reuters) – Re-engineering an HIV patient’s own immune cells to find and destroy the virus succeeded in controlling the infection in a small first-in-human study, but researchers said work is ...

April 21 (Reuters) – The U.S. Food and Drug Administration has approved Merck’s once-daily, oral, combination regimen for HIV infections, the drugmaker said on Tuesday, giving patients another ...

More than four decades into the HIV epidemic, progress has transformed treatment and prevention, yet the need remains urgent. Today, an estimated 1.2 million people in the United States are living ...

Keep the news in the Wayback Machine. Sign Fight for the Future's letter. Please Don't Scroll Past This Can you chip in? The Internet Archive partners with libraries, archives, and institutions across ...

Please provide your email address to receive an email when new articles are posted on . Previous studies have shown that DOR/ISL was noninferior to continuing current HIV therapies At 48 weeks, 91.8% ...